Abstract B003: Combinatorial therapies of neratinib for HER2-amplified cancer
Sign Up to like & getrecommendations! Published in 2019 at "Molecular Cancer Therapeutics"
DOI: 10.1158/1535-7163.targ-19-b003
Abstract: Activation of HER2 signaling by amplification or overexpression of ERBB2 (HER2) is associated with the development and progression of breast cancer. Neratinib is an irreversible, pan-HER tyrosine kinase inhibitor which selectively inhibits EGFR, HER2 and… read more here.
Keywords: combinatorial therapies; cancer; her2 amplified; neratinib her2 ... See more keywords